新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Cancer Prev Res:单一剂量的HPV疫苗就可保护女性个体有效抵御宫颈癌

Cancer Prev Res:单一剂量的HPV疫苗就可保护女性个体有效抵御宫颈癌

来源:生物谷 2013-11-05 23:59

2013年11月5日 讯 /生物谷BIOON/ --近日,刊登在国际杂志Cancer Prevention Research上的一篇研究论文中,来自美国国家癌症研究所的研究人员通过研究表示,注射单一剂量人乳头瘤病毒(HPV)疫苗的女性机体中可以产生有效抵御病毒的抗体,而且这种抗体在血液中可以维持长达4年以上;这也就表明,单一剂量的HPV疫苗对于个体产生长期机体免疫防御力以及抵御HPV的感染非常重要。

文章中,研究者Mahboobeh Safaeian表示,我们试图去评估两倍剂量或者单一剂量的HPV16/18 L1 VLP疫苗(Cervarix)是否可以诱导机体产生强效的免疫力,结果发现,接受单一剂量疫苗注射的女性体内的HPV16和18抗体的水平可以在体内维持4年。

研究者对78名、192名以及120名女性分别进行单一剂量、双倍剂量以及三倍剂量的疫苗注射,同时以113名不进行疫苗注射的女性进行对比,结果发现,上述接种三类剂量疫苗的女性,100%的女性都可以产生HPV16和18的抗体,而且可以维持长达四年。

研究者在实验中发现,接种单一剂量疫苗的女性相比接种全部三倍剂量疫苗的女性,前者的血液中抗体水平相对较低,但是其水平更加稳定。该项研究或为制定疫苗的接种策略提供可行的建议,而且也可以帮助降低疫苗的成本,使得更多女性个体获益。(生物谷Bioon.com)

Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial

Mahboobeh Safaeian1, Carolina Porras2, Yuanji Pan1, Aimee Kreimer1, John T. Schiller1, Paula Gonzalez2,4, Douglas R. Lowy1, Sholom Wacholder1, Mark Schiffman1, Ana C. Rodriguez2, Rolando Herrero2,4, Troy Kemp1, Gloriana Shelton1, Wim Quint3, Leen-Jan van Doorn3, Allan Hildesheim1, Ligia A. Pinto1, for the CVT Group

The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle (VLP) vaccine. Live-attenuated viral vaccines, but not simple-subunit vaccines, usually induce durable lifelong antibody responses after a single dose. It is unclear whether noninfectious VLP vaccines behave more like live-virus or simple-subunit vaccines in this regard. To explore the likelihood that efficacy will persist longer term, we investigated the magnitude and durability of antibodies to this vaccine by measuring HPV16- and HPV18-specific antibodies by VLP-ELISA using serum from enrollment, vaccination, and annual visits through four years in four vaccinated groups; one-dose (n = 78), two-doses separated by one month (n = 140), two doses separated by six months (n = 52), and three scheduled doses (n = 120, randomly selected). We also tested enrollment sera from n = 113 HPV16- or HPV18 L1-seropositive women prevaccination, presumably from natural infection. At four years, 100% of women in all groups remained HPV16/18 seropositive; both HPV16/18 geometric mean titers (GMT) among the extended two-dose group were non-inferior to the three-dose group, and ELISA titers were highly correlated with neutralization titers in all groups. Compared with the natural infection group, HPV16/18 GMTs were, respectively, at least 24 and 14 times higher among the two-dose and 9 and 5 times higher among one-dose vaccinees. Antibody levels following one-dose remained stable from month 6 through month 48. Results raise the possibility that even a single dose of HPV VLPs will induce long-term protection. Cancer Prev Res; 6(11); 1242–50. ©2013 AACR.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库